Boston Scientific Corp. (NYSE:BSX) landed FDA clearance for its Infinion 16 percutaneous lead, designed for use with the company’s Precision Plus spinal cord stimulator system to control chronic pain.
The Infinion 16 lead is the first 16-contact percutaneous lead on the global market, doubling the previous max of eight stimulating contacts, according to the Natick, Mass.-based med-tech titan.
BSX’s spinal cord stimulator leads are designed to mask pain signals to the brain by delivering electrical pulses from an implantable pulse generator.
"With the launch of the Infinion 16 lead, Boston Scientific continues its commitment to innovation by offering pain management physicians more choices to help optimize pain relief for their patients," Maulik Nanavaty, president of BSX’s neuromodulation division, said in prepared remarks.
Boston Scientific Corp. (NYSE:BSX) nearly sold its neurostimulation division to Stryker Corp. (NYSE:SYK) late last year, but the Natick, Mass.-based medical device maker spiked the deal when the bid didn’t rise high enough. The company then doubled down on the pain management division with a $78 million buyout of Intelect Medical Inc., developer of the Guide deep-brain stimulation programming system.
Boston Scientific won FDA clearance for lead anchors for its partially implantable Precision Plus PNS device in March.
Breast tissue expanders used in IDE Trail
Breast reconstruction technology company AirXpanders Inc. treated the first patient in an investigational device exemption trail of its new post-mastectomy tissue expansion device. Read more
Ascendx Spine starts EU commercialization
Ascendx Spine started the European commercialization of its Ascendx VCF repair system and its Acu-Cut vertebral augmentation system after winning CE Mark approval. strong>Read more